SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
08
11
2022
accepted:
20
02
2023
revised:
13
02
2023
medline:
8
5
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
The kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in allogeneic and autologous stem cell transplantation (allo-HSCT, ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) are of utmost importance for estimating risk of infection. A prospective multicenter registry-based cohort study, conducted from December 2020 to July 2022 was used to analyze antibody waning over time, booster effect and the relationship of antibody response and breakthrough infection in 572 recipients (429 allo-HSCT, 121 ASCT and 22 CAR-T cell therapy). A significant decline in antibody titers was observed at 3 and 6 months after full vaccination in recipients without pre-vaccine SARS-CoV-2 infection, whereas recipients infected prior to vaccination showed higher and stable antibody titers over time. In poor responders, a booster dose was able to increase antibody titers in 83% of allo-HSCT and 58% of ASCT recipients but not in CART-T cell recipients [0%] (p < 0.01). One-year cumulative incidence of breakthrough infection was 15%, similar among cell therapy procedures. Immunosuppressive drugs at the time of vaccination [hazard ratio (HR) 1.81, p = 0.0028] and reduced intensity conditioning (HR 0.49, p = 0.011) were identified as the only conditions associated with different risk of breakthrough infection in allo-HSCT recipients. Antibody titers were associated with breakthrough infection and disease severity. No death was observed among the 72 breakthrough infections. Antibody level decay after the first two vaccine doses was common except in recipients with pre-vaccination SARS-CoV-2 infection. Poorly responding allo-HSCT recipients showed a response advantage with the booster as compared to ASCT and, especially, the null response found in CAR-T cell recipients. Antibody titers were positively correlated with the risk of breakthrough SARS-CoV-2 infection which was mainly driven by the immunosuppression status.
Identifiants
pubmed: 36854892
doi: 10.1038/s41409-023-01946-0
pii: 10.1038/s41409-023-01946-0
pmc: PMC9974060
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Antibodies, Viral
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-580Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Ann Hematol. 2022 Sep;101(9):2053-2067
pubmed: 35780254
J Med Biochem. 2021 Sep 03;40(4):335-340
pubmed: 34616223
Transplant Cell Ther. 2022 Oct;28(10):706.e1-706.e10
pubmed: 35914727
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Leukemia. 2021 Oct;35(10):2885-2894
pubmed: 34079042
Nat Microbiol. 2022 Dec;7(12):1996-2010
pubmed: 36357712
J Clin Microbiol. 2022 Jan 19;60(1):e0174621
pubmed: 34705539
Leuk Lymphoma. 2022 Mar;63(3):538-550
pubmed: 34668835
J Med Virol. 2023 Jan;95(1):e28397
pubmed: 36504019
Lancet Infect Dis. 2022 Nov;22(11):1535-1537
pubmed: 36179744
Stat Med. 1999 Mar 30;18(6):695-706
pubmed: 10204198
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
J Hematol Oncol. 2022 May 7;15(1):54
pubmed: 35526045
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Blood. 2022 Mar 10;139(10):1439-1451
pubmed: 34662390
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Exp Hematol Oncol. 2020 Aug 25;9:21
pubmed: 32864192
J Hematol Oncol. 2022 Mar 18;15(1):27
pubmed: 35303906
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
Blood Adv. 2022 Feb 8;6(3):774-784
pubmed: 34844263
Lancet Haematol. 2021 Oct;8(10):e681-e683
pubmed: 34487683
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Leukemia. 2021 Dec;35(12):3585-3588
pubmed: 34750508
Viruses. 2022 Aug 30;14(9):
pubmed: 36146735
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2204336119
pubmed: 35858382
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
Diagnostics (Basel). 2022 Jun 09;12(6):
pubmed: 35741236
Blood. 2022 Aug 4;140(5):445-450
pubmed: 35588468
Blood Cancer J. 2023 Jan 5;13(1):8
pubmed: 36599843
Am J Hematol. 2022 Jan 1;97(1):30-42
pubmed: 34695229
Leukemia. 2022 Jun;36(6):1467-1480
pubmed: 35488021
Blood. 2022 Aug 18;140(7):782-785
pubmed: 35605185
J Clin Microbiol. 2022 Jun 15;60(6):e0048221
pubmed: 35249377
Transplant Cell Ther. 2022 Apr;28(4):214.e1-214.e11
pubmed: 35092892
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
Bone Marrow Transplant. 2022 Nov;57(11):1727-1731
pubmed: 36028758
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
J Infect Dis. 2022 Apr 1;225(7):1124-1128
pubmed: 34792136